PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Cancer Research0 citations

Evaluation of Lorigerlimab in Advanced Solid Tumors: A Phase 2 Multicohort Study

Abstract CT279: A phase 2 multicohort study to evaluate lorigerlimab (PD-1 x CTLA-4) in participants with advanced solid tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHelen D. ClarkKRKelly M. RangelSRShawana N. Richard

Discussion

Loading...

Member takes

Overview

This phase 2 multicohort study evaluates the efficacy and safety of lorigerlimab in advanced solid tumors, highlighting its potential in treating specific cancer types.

Key Points

  • The study aims to evaluate the antitumor activity and safety of lorigerlimab in patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.
  • Open-label, multicohort, phase 2 design
  • Participants with PROC and CCGC received lorigerlimab intravenously every 3 weeks
  • Primary endpoint: objective tumor response; secondary endpoints include safety and progression-free survival
  • Tumor assessments every 9 weeks for the first year, then every 12 weeks until discontinuation
  • Enrollment ongoing since May 2025
  • Details on specific efficacy and safety outcomes are pending as enrollment is ongoing
  • Conducting assessments for tumor size changes and overall response rates
  • Evaluating tolerability and duration of response in the defined cohorts

Cite This Study

Clark et al. (2026) studied this question.

synapsesocial.com/papers/69e471ef010ef96374d8e2f6https://doi.org/10.1158/1538-7445.am2026-ct279
View Full Paper
Ask AI
Bookmark
Share